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Introduction
Atrial fibrillation (AF) remains the most com-
mon cardiac arrhythmia, affecting 3–5% of the 
population aged 65–75 years. It is associated with 
substantial mortality and morbidity, particularly 
due to stroke. Over 90% of clinically apparent em-
bolisms in AF originate from the left atrial append-
age (LAA). Nowadays, oral anticoagulation still 
remains the state-of-the-art therapy for patients 
with AF. Since the first percutaneous LAA occlu-
sion (LAAO) in 2002 [1] many studies have shown 
the safety and efficacy of this therapy using differ-
ent closure devices [2–9]. Percutaneous LAAO is 
a valuable therapeutic option for selected high-risk 
patients with AF and contraindications for oral an-
ticoagulation therapy. Currently, there are several 
types of devices available for LAAO: Watchman, 
ACP-Amplatzer Cardiac Plug, Coherex WaveCrest, 
and Cardia Ultraseal. These devices represent 
a variety of designs and thus offer uniquely different 
approaches to the mechanical closure of the LAA. 
The Cardia Ultraseal LAA closure device is a newly 
designed device, representing a novel concept of 
LAAO. Recently, first in vivo study demonstrated 
the feasibility and safety of Cardia device in the ca-
nine model [10]. Herein, we present first-in-human 
original experience with Cardia device.
The Cardia Ultraseal LAA device is a unique next 
generation design which combines the advantages of 
a distal anchoring bulb with the proven performance 
of a proximal sail to close the LAA orifice. These two 
components are connected with a dual articulating 
joint allowing the device to conform naturally to the 
most tortuous of LAA anatomies. It is constructed 
with a nitinol frame and designed in a manner which 
produces a soft and flexible device. The combination 
of these characteristics provides an attractive design 
which easily conforms to the LAA and surrounding 
structures with minimal risk of residual shunt or ana-
tomical distortion (Fig. 1A). The device is available in 
9 different bulb sizes ranging from 16 mm to 34 mm. 
The sail diameter is 6 mm larger than the distal bulb 
and delivery sheath sizes range from 10 Fr to 12 Fr 
(Fig. 1A, B).
Sizing and device selection
The LAA should be measured at a depth of 
10–12 mm from the intended sail location. This rep-
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resents the landing zone for the anchoring hooks 
of the device. The selected device should have 
a bulb diameter at least 25% to 33% greater than the 
largest diameter of the landing zone. The proximal 
pin of the device is grasped using the delivery 
forceps, then the device is pulled into the loader 
and flushed. The distal end of the sheath should 
be positioned in the LAA at the intended landing 
zone. Holding the sheath in place, the forceps are 
advanced until the entire bulb section of the de-
vice is deployed. The anchor markers of the bulb 
should appear to have a non-symmetric shape. This 
indicates that the bulb is properly under compres-
sion. The bulb should be kept in the same position 
and then the sheath is retracted until the entire 
sail section of the device is deployed. To confirm 
a stable position, a gentle pushing and pulling 
maneuver should be performed. Transesophageal 
echocardiography (TEE) should confirm the posi-
tion of the device and the distance of the sail from 
Figure 1. A. The Cardia Ultraseal left atrial appendage (LAA) device consists of proximal disc (to cover the LAA orifice) 
and a distal atraumatic soft lobe (to secure the device in the LAA) connected by a double articulating center for optimal 
positioning and repositioning within the appendage; 12 stabilizing anchors enabling secure engagement to the LAA; 
The discs (B) are 6 mm larger for lobe sizes 16 mm to 32 mm (A). B. The Cardia Ultraseal LAA device selection. C–H. 
Technique of implantation (C. Sizing the orifice of LAA; D. Landing zone — approximately 10–12 mm from the orifice; 
E. Positioning of the sheath; F. Positioning of the body of the device; G. Opening the sail of the device — the device 
is fully opened, but still connected with delivery system; H. Releasing of the device; LZD — landing zone diameter). 
I, J. The optimal position of Cardia Ultraseal LAA device in LAA of patient 4 documented in the two-dimensional-
transesophageal echocardiography (I) and three-dimensional-transesophageal echocardiography imaging (J).
other cardiac structures including mitral valve and 
pulmonary veins should be at least 5 mm. If the 
position of the device and complete closure of LAA 
is confirmed in TEE, the device can be released. 
The device can easily be partially and/or fully re-
trieved and redeployed (maximum 5 times) before 
release (Fig. 1C–H).
Methods and results
Six patients aged 64–70 (mean 72.8) years 
were selected for LAA closure. The primary 
indications for LAAO were gastrointestinal bleed-
ings and nose bleedings. Mean HAS-BLED and 
CHA2DS2VASC scale were 3.8. Mean LAA diam-
eter was 20.8 (range 14.7–25) mm as measured by 
TEE and 20.5 (range 14.3–28) mm as measured 
by fluoroscopy. Patient data, indication for LAA 
closure, anatomy, and diameter of LAA are sum-
marized in Table 1.
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Patients were catheterized and prepared for 
the LAA closure procedure utilizing standard tech-
niques. The transseptal puncture was performed 
under TEE guidance. The delivery sheath was 
positioned within the LAA under fluoroscopic and 
TEE guidance. In 5 patients, the Cardia Ultraseal 
LAA device was implanted without any difficulty or 
technical problems. Procedure time was 58 (range 
45–80) min and fluoroscopy time was 18.9 (range 
19.7–34) min. The final position of all devices 
was correct, and there was no residual leak docu-
mented by TEE imaging (Fig. 1I, J). In 1 patient 
(No. 2), the anatomy of the LAA and surrounding 
structures were not suitable for device implanta-
tion and the procedure was discontinued. In the 
1-month-follow-up TEE examination, the position 
of all devices was optimal. There was no thrombus 
formation, and no residual leak and all LAAs have 
been fully occluded.
In summary, the Cardia Ultraseal LAA closure 
device presents a new concept in LAAO proce-
dures. The construction of the device is unique, and 
the device is easy to use and suitable for a broad 
spectrum of LAA anatomy. The dual articulating 
joint is very useful and allows superior position-
ing of the device in difficult angulated LAAs. Due 
to its soft construction and flexibility, the device 
fully adapts to the LAA anatomy and the sail easily 
conforms to the surrounding structures closing the 
LAA orifice with a very high rate of total occlusion. 
Our initial experience with this device included 
5 implants with 30-day follow-up. An extensive 
clinical investigating is warranted to confirm the 
benefits of the Cardia Ultraseal LAA device and 
this new unique approach to close LAA.
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Table 1. Patient data, indication for left atrial appendage (LAA) closure, anatomy and diameter of LAA, 
device selection, procedural parameters.
No. Sex Age 
[years]
Indication 
for LAA 
closure
A B Diameter 
of LAA 
Echo 
[mm]
Diameter 
of LAA 
Fluoro 
[mm]
Anatomy 
of the 
LAA
LAA  
device 
size
Fluoroscopy  
time  
[min]
Procedure 
time  
[min]
1 M 79 a 4 3 14.7 14.6 Cauliflower 20 19.7 80
2 M 78 a 5 6 23 14.3 Windsock 26/18 23.8 100
3 M 64 b 2 3 19 18.2 Cactus 24 34 45
4 M 64 a 4 3 22 21.9 Windsock 26 16.9 60
5 F 75 c 3 3 21 26 Chicken-
wing
32 10.6 55
6 F 77 a 5 5 25 28 Windsock 30 13.1 60
Mean 72.8 3.8 3.8 20.8 20.5 19.7 65
A — HAS-BLED scale; B — CHA2DS2VASC scale; Indication for LAA closure: a — gastrointestinal bleeding; b — bleeding from the nose;  
c — bleeding hemorrhoids; Patient No. 2 — procedure abounded; M — male; F — female
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